Positive News SentimentPositive NewsNASDAQ:CLYM Climb Bio (CLYM) Stock Price, News & Analysis $2.25 -0.15 (-6.25%) As of 09/12/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Climb Bio Stock (NASDAQ:CLYM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Climb Bio alerts:Sign Up Key Stats Today's Range$2.24▼$2.4550-Day Range$1.26▼$2.4852-Week Range$1.05▼$8.79Volume404,709 shsAverage Volume615,476 shsMarket Capitalization$152.47 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview Climb Bio Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need. At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling. This integrated system enables rapid identification, optimization and high-throughput screening of novel protein candidates, accelerating the transition from target validation to preclinical development while maintaining stringent quality and manufacturability criteria. Climb Bio has assembled a portfolio of preclinical programs that leverage its platform to generate next-generation biologics in immuno-oncology and related disease areas. The company is advancing these assets through lead optimization and IND-enabling studies, with a view toward first-in-human clinical trials. By focusing on modalities that can modulate immune responses and tumor microenvironments, Climb Bio aims to create differentiated therapeutic candidates with broad applicability. Headquartered in the greater Boston area, a major hub for life science innovation, Climb Bio operates dedicated research laboratories and maintains a leadership team with extensive experience in biopharmaceutical R&D and strategic partnerships. Looking ahead, the company plans to expand its pipeline through collaborations with academic institutions and industry partners, positioning its platform to address additional disease targets and serve global markets.AI Generated. May Contain Errors. Read More Climb Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreCLYM MarketRank™: Climb Bio scored higher than 74% of companies evaluated by MarketBeat, and ranked 284th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingClimb Bio has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Upside PotentialClimb Bio has a consensus price target of $9.00, representing about 300.0% upside from its current price of $2.25.Amount of Analyst CoverageClimb Bio has only been the subject of 2 research reports in the past 90 days.Read more about Climb Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Climb Bio are expected to grow in the coming year, from ($1.57) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Climb Bio is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Climb Bio is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClimb Bio has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Climb Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.06% of the float of Climb Bio has been sold short.Short Interest Ratio / Days to CoverClimb Bio has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClimb Bio does not currently pay a dividend.Dividend GrowthClimb Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.06% of the float of Climb Bio has been sold short.Short Interest Ratio / Days to CoverClimb Bio has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media3.6 / 5News Sentiment1.57 News SentimentClimb Bio has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Climb Bio this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CLYM on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows6 people have added Climb Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Climb Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,540.00 in company stock.Percentage Held by InsidersOnly 0.80% of the stock of Climb Bio is held by insiders.Percentage Held by Institutions69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Climb Bio's insider trading history. Receive CLYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Climb Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLYM Stock News HeadlinesClimb Bio to host webcast highlighting CLYM116, IgA Nephropathy opportunitySeptember 4, 2025 | msn.comClimb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025September 4, 2025 | globenewswire.comTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do… | Brownstone Research (Ad)UPDATE – Climb Bio to Present at Upcoming September 2025 Investor ConferencesAugust 25, 2025 | globenewswire.comClimb Bio to Present at Upcoming September 2025 Investor ConferencesAugust 25, 2025 | globenewswire.comClimb Bio, Inc. (NASDAQ:CLYM) surges 12%; private equity firms who own 54% shares profited along with institutionsAugust 17, 2025 | finance.yahoo.comBaird Initiates Coverage of Climb Bio (CLYM) with Outperform RecommendationAugust 16, 2025 | msn.comClimb Bio initiated with an Outperform at Baird on budoprutug potentialAugust 15, 2025 | msn.comSee More Headlines CLYM Stock Analysis - Frequently Asked Questions How have CLYM shares performed this year? Climb Bio's stock was trading at $1.80 at the beginning of the year. Since then, CLYM shares have increased by 25.0% and is now trading at $2.25. How were Climb Bio's earnings last quarter? Climb Bio, Inc. (NASDAQ:CLYM) released its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.06. Who are Climb Bio's major shareholders? Climb Bio's top institutional investors include Diadema Partners LP (1.04%), Nan Fung Trinity HK Ltd. (0.69%), Shay Capital LLC (0.61%) and Geode Capital Management LLC (0.46%). View institutional ownership trends. How do I buy shares of Climb Bio? Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/12/2025Today9/13/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLYM Previous SymbolNASDAQ:CLYM CIK1768446 Webclimbbio.com Phone866-857-2596FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Price Target for Climb Bio$9.00 High Price Target$10.00 Low Price Target$7.00 Potential Upside/Downside+300.0%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$73.90 million Net MarginsN/A Pretax MarginN/A Return on Equity-23.10% Return on Assets-22.47% Debt Debt-to-Equity RatioN/A Current Ratio14.08 Quick Ratio14.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.15 per share Price / Book0.71Miscellaneous Outstanding Shares67,760,000Free Float67,222,000Market Cap$152.46 million OptionableN/A Beta-0.05 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CLYM) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.